Nachrichten zur Syndax Pharmaceuticals Inc. Aktie

Syndax Pharmaceuticals: 57 USD Kursziel treffen auf die anstehenden MAXPIRe-Studiendaten

Syndax Pharmaceuticals (SNDX) adressiert mit seinem Geschäftsmodell Nischenmärkte für immunvermittelte Krankheiten sowie Onkologie bei aktuell steigenden Umsätzen. Analysten der Citigroup…

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

…

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -22.22% and -11.16%, respectively, for the quarter ended June 2026. Do the…

Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know

Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the…

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative…

Syndax Pharmaceuticals: Krebsspezialist laut JPMorgan mit Kursverdoppelungspotenzial!

Mit drei FDA-Zulassungen in einem Jahr startet die Kommerzialisierung. Mit der Behandlung von akuter Leukämie und cGVHD soll ein über 10…

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -21.88% and +10.21%, respectively, for the quarter ended December 2025. Do the…

Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow

…

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

…

Syndax Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation

…

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +5.41% and -5.79%, respectively, for the quarter ended September 2025. Do the…

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

…

Syndax Pharmaceuticals: Guggenheim sieht eine Unterbewertung mit 111% Kurspotenzial!

Syndax Pharmaceuticals (SNDX) hat am 04. August 2025 den Bericht für das 2. Quartal veröffentlicht. Demnach wurde ein Umsatz in…

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

…

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the…

Syndax Announces Participation in June Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative…

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript

…

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the…

Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com

Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call…

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an…

Nachrichten zur Syndax Pharmaceuticals Inc. Aktie

Syndax Pharmaceuticals: 57 USD Kursziel treffen auf die anstehenden MAXPIRe-Studiendaten

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals: Krebsspezialist laut JPMorgan mit Kursverdoppelungspotenzial!

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates

Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Syndax Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

Syndax Pharmaceuticals: Guggenheim sieht eine Unterbewertung mit 111% Kurspotenzial!

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

Syndax Announces Participation in June Investor Conferences

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates

Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript

Earnings call: Syndax Pharmaceuticals outlines robust Q1 2024 performance By Investing.com

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Call Transcript

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials By Investing.com

Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript

dpa-AFX ProFeed